Elizabeth M Swisher
Overview
Explore the profile of Elizabeth M Swisher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
10297
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nesic K, Rybinski K, Ratnayake G, Ho G, Lim R, Radke M, et al.
Clin Transl Med
. 2025 Mar;
15(3):e70274.
PMID: 40074693
No abstract available.
2.
Swisher E, Harris H, Knerr S, Theoryn T, Norquist B, Brant J, et al.
JAMA Netw Open
. 2025 Mar;
8(3):e250185.
PMID: 40053353
Importance: Best practices for improving access to assessment of hereditary cancer risk in primary care are lacking. Objective: To compare 2 population-based engagement strategies for identifying primary care patients with...
3.
Oluloro A, Swisher E, Gray H, Goff B, Doll K
J Natl Cancer Inst
. 2024 Dec;
PMID: 39700440
Background: Racial and ethnic minorities remain underrepresented in gynecologic cancer clinical trials despite disproportionately worse oncologic outcomes. Research shows differential racial enrollment patterns due to comorbidity-based exclusion criteria (CEC). Our...
4.
Conner S, Theoryn T, Dusic E, Beers F, Knerr S, Norquist B, et al.
Genet Med
. 2024 Nov;
27(4):101307.
PMID: 39484797
Purpose: This study sought to better understand primary care providers' readiness to conduct population-based risk assessment and offer genetic testing for hereditary cancer. Methods: Sixty primary care providers completed a...
5.
Venkatachalam A, Correia C, Peterson K, Hou X, Schneider P, Strathman A, et al.
Mol Cancer
. 2024 Oct;
23(1):224.
PMID: 39375715
Recent studies indicate that replication checkpoint modulators (RCMs) such as inhibitors of CHK1, ATR, and WEE1 have promising monotherapy activity in solid tumors, including platinum-resistant high grade serous ovarian cancer...
6.
Tee X, Hazard E, Latorre-Esteves E, Kohrn B, Ghezelayagh T, Fredrickson J, et al.
Gynecol Oncol
. 2024 Aug;
190:18-27.
PMID: 39128337
Background: Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations,...
7.
Nesic K, Krais J, Wang Y, Vandenberg C, Patel P, Cai K, et al.
Mol Cancer
. 2024 Aug;
23(1):158.
PMID: 39103848
PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PARPi resistance...
8.
Ghezelayagh T, Kohrn B, Fredrickson J, Krimmel-Morrison J, Latorre-Esteves E, Tee X, et al.
Oncogene
. 2024 Jun;
43(31):2421-2430.
PMID: 38918516
Somatic TP53 mutations are prevalent in normal tissue but little is known about their association with cancer risk. Cervical liquid-based cytology (LBC), commonly known as Pap test, provides an accessible...
9.
Manchanda R, Sun L, Sobocan M, Rodriguez I, Wei X, Kalra A, et al.
J Natl Compr Canc Netw
. 2024 Jun;
22(2 D).
PMID: 38866043
Background: Parallel panel germline and somatic genetic testing of all patients with ovarian cancer (OC) can identify more pathogenic variants (PVs) that would benefit from PARP inhibitor (PARPi) therapy, and...
10.
Liu J, Xiong N, Wenham R, Wahner-Hendrickson A, Armstrong D, Chan N, et al.
Gynecol Oncol
. 2024 May;
187:105-112.
PMID: 38759516
Objective: Combination cediranib/olaparib has reported activity in relapsed ovarian cancer. This phase 2 trial investigated the activity of cediranib/olaparib in relapsed ovarian cancer and its association with homologous recombination deficiency...